In Brief: Rhone-Poulenc Rorer's Taxotere
Executive Summary
Rhone-Poulenc Rorer's Taxotere: Anticancer agent for treatment of anthracycline-resistant advanced or metastatic breast cancer deemed "approvable" by FDA Oct. 27, 10 days following a unanimous recommendation for approval by FDA's Oncologic Drugs Advisory Committee on Oct. 17...